Aptus Pharma Limited's initial public offering (IPO) has demonstrated exceptional investor interest through its final day of subscription, with Aptus Pharma's stock price set at ₹65-70 per share reflecting strong market reception. The ₹13.02 crore IPO reached 22.27 times by 5:04:42 PM on day three.
Aptus Pharma IPO individual investors segment leads with exceptional 31.43 times subscription, whilst non-institutional investors show exceptional 28.75 times participation and qualified institutional buyers demonstrate moderate participation at 1.24 times, whilst anchor investors show complete participation at 1.00 times and market makers show complete participation at 1.00 times.
IPO Subscription Status
Invest in Indian Markets and Unlock Future Potential With 5paisa!
| Date | QIB (Ex Anchor) | NII | Individual Investors | Total |
|---|---|---|---|---|
| Day 1 (September 23) | 0.00 | 4.78 | 1.77 | 1.92 |
| Day 2 (September 24) | 0.81 | 6.16 | 5.46 | 4.29 |
| Day 3 (September 25) | 1.24 | 28.75 | 31.43 | 22.27 |
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (₹ Cr.) |
|---|---|---|---|---|
| Anchor Investors | 1.00 | 5,28,000 | 5,28,000 | 3.70 |
| QIB (Ex Anchor) | 1.24 | 3,52,000 | 4,36,000 | 3.05 |
| Non-Institutional Buyers | 28.75 | 2,66,000 | 76,48,000 | 53.54 |
| Individual Investors | 31.43 | 6,20,000 | 1,94,88,000 | 136.42 |
| Total | 22.27 | 12,38,000 | 2,75,72,000 | 193.00 |
Key Highlights - Day 3:
- Overall subscription reached exceptional 22.27 times, showing remarkable surge from day two's 4.29 times with explosive final-day momentum
- Individual investors displaying exceptional confidence at 31.43 times, building dramatically from day two's 5.46 times showing overwhelming retail enthusiasm for this pharmaceutical offering
- Non-institutional investors showing exceptional performance at 28.75 times, building substantially from day two's 6.16 times with bNII segment leading at 30.64 times
- Qualified institutional buyers showing moderate performance at 1.24 times, building from day two's 0.81 times but remaining the weakest performing category
- Total applications reached 5,590, indicating substantial investor participation for this SME IPO
- Cumulative bid amount reached ₹193.00 crores, representing massive 1,482% of the issue size of ₹13.02 crores
Key Highlights - Day 2:
- Overall subscription reached moderate 4.29 times, showing improvement from day one's 1.92 times
- Non-institutional investors showing moderate performance at 6.16 times, building from day one's 4.78 times
- Individual investors displaying moderate confidence at 5.46 times, building significantly from day one's 1.77 times
- Qualified institutional buyers showing limited performance at 0.81 times, building from day one's 0.00 times
Key Highlights - Day 1:
- Overall subscription reached limited 1.92 times, showing positive initial investor interest in this SME pharmaceutical IPO
- Non-institutional investors showing moderate performance at 4.78 times, indicating early HNI confidence
- Individual investors displaying limited confidence at 1.77 times, showing measured retail sentiment
- Qualified institutional buyers showing no participation at 0.00 times on opening day
About Aptus Pharma Ltd.
Incorporated in 2010, Aptus Pharma Limited is engaged in marketing and distribution of finished pharmaceutical formulations across multiple therapeutic areas including antacids, pain management, antibiotics, cardiology, and neuropsychiatry, operating through four brands: Aptus Pharma, Aptus CD care, Aptus Wellcare, and Aptus Global, with 194 pharmaceutical formulations and distribution network of 125 distributors.
5paisa Capital Ltd
